Lee JS, Lee EJ, Yeom J, et al. - Compared with blood samples, urine samples are more easily collected; therefore, researchers sought to distinguish such a biomarker-based on urinary proteomics which could distinguish patients with systemic lupus erythematosus (SLE) from healthy controls (HCs). Researchers collected urine samples from 76 SLE patients who visited rheumatology clinics in 2019 at Asan medical center and from 25 HCs. They examined urine proteins using the sequential windowed acquisition of all theoretical fragment ion spectra-mass spectrometry, and the candidate marker was confirmed by enzyme-linked immunosorbent assay. The diagnostic value of the candidate biomarker was ascertained using receiver operating characteristic curve analysis. In this study, 153 were differentially expressed in urine samples from HCs out of 1,157 proteins quantified. The outcomes demonstrate that the urine amount of β-2 glycoprotein level can be an appropriate screening tool in a clinical setting when SLE is suspected.